Dr. Uday Kumar R is an assistant professor at the Amrita School of Pharmacy in Kochi, where he teaches pharmacy practice. He earned his Ph.D. from KLE University in Belagavi, Karnataka, in 2021 after completing his Pharm.D. at Rajiv Gandhi University of Health Sciences in Bangalore, Karnataka, in 2016. worked as a technical assistant for the Indian Pharmacopoeia Commission in Ghaziabad (UP) at Kasturba Medical College and Hospital in Mangalore, Karnataka, in 2021. From 2021 to 2022, he was employed as a Scientist C in the Indian Council of Medical Research's Division of Epidemiology and Communicable Disease in New Delhi. From 2012 to 2023, he was also employed as a Scientist C at the All India Institute of Medical Sciences in Rishikesh, Uttarakhand. 

Completed Pharmacogenomics projects:

1. Study of clinical factors and klotho gene single nucleotide polymorphism in kidney transplant recipients

2. Study of association between adverse drug reactions and drug metabolic enzyme genetic polymorphisms in tuberculosis prevention therapy

3. Study of cyp2c19 polymorphisms and its association with clopidogrel resistance in a tertiary care hospital

4. Impact Of Cyp2c9, Vkorc1, Cyp4f2 Genetic Polymorphism and Clinical Factors on Vitamin K Antagonist (Vka) Dosing in South Indian Population

Ongoing Pharmacogenomics projects:

1. Development and validation of a prediction model for personalized NOAC therapy in patients with thromboembolic events by integrating Pharmacogenomics and cost-effectiveness- A prospective Interventional study

2. Investigational Report on Autoimmune Atypical Parkinsonism: Whole Exome Sequencing and Clinical Outcome Correlation

3. A study on the prognostic implications of TP53 gene mutations in CART-cell therapy for patients with non-Hodgkin's B-cell lymphoma

4. Recurrent thromboembolism in patients with myocardial infarction, stroke, and coronary artery disease on clopidogrel therapy: the role of ABCB1 genetic polymorphisms.

5. Recurrent thromboembolism in patients with myocardial infarction, stroke, and coronary artery disease on clopidogrel therapy: the role of P2Y12 genetic polymorphisms.